Search results
Showing 886 to 900 of 1329 results for nice quality standards or clinical guidelines
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
Prevena incision management system for closed surgical incisions (MIB173)
NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .
Lung texture analysis for measuring interstitial lung diseases (MIB272)
NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
GPs help to bring a primary care perspective to the guidance that we produce.
GPs help to bring a primary care perspective to the guidance that we produce.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.
In development Reference number: GID-QS10094 Expected publication date: 01 July 2026
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .